Fox Run Management L.L.C. bought a new position in shares of Bristol-Myers Squibb Co (NYSE:BMY) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 16,700 shares of the biopharmaceutical company’s stock, valued at approximately $1,064,000.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in BMY. Tradewinds Capital Management LLC grew its holdings in shares of Bristol-Myers Squibb by 34.6% in the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 500 shares during the period. Atlantic Trust LLC acquired a new position in shares of Bristol-Myers Squibb in the 2nd quarter valued at $111,000. American National Bank grew its holdings in shares of Bristol-Myers Squibb by 11.7% in the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 225 shares during the period. Blue Chip Partners Inc. grew its holdings in shares of Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 15 shares during the period. Finally, Heritage Trust Co acquired a new position in shares of Bristol-Myers Squibb in the 1st quarter valued at $123,000. 69.66% of the stock is owned by hedge funds and other institutional investors.
Shares of Bristol-Myers Squibb Co (NYSE BMY) opened at $60.96 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb Co has a 52-week low of $46.01 and a 52-week high of $66.10. The company has a market cap of $100,657.05, a PE ratio of 24.00, a price-to-earnings-growth ratio of 2.33 and a beta of 1.18.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be given a dividend of $0.40 per share. The ex-dividend date is Thursday, January 4th. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a yield of 2.62%. Bristol-Myers Squibb’s payout ratio is 61.42%.
Several equities analysts have recently issued reports on the stock. Barclays boosted their price target on shares of Bristol-Myers Squibb from $58.00 to $65.00 and gave the company an “equal weight” rating in a report on Friday, October 13th. Jefferies Group lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price target for the company. in a report on Monday, October 16th. BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a report on Thursday, October 12th. Leerink Swann boosted their price target on shares of Bristol-Myers Squibb from $61.00 to $72.00 and gave the company an “outperform” rating in a report on Monday, October 23rd. Finally, Citigroup boosted their price target on shares of Bristol-Myers Squibb to $72.00 and gave the company a “buy” rating in a report on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average price target of $64.42.
In other news, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Theodore R. Samuels II bought 4,000 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was purchased at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the acquisition, the director now owns 22,000 shares in the company, valued at approximately $1,370,600. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Fox Run Management L.L.C. Takes Position in Bristol-Myers Squibb Co (BMY)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.com-unik.info/2017/12/23/fox-run-management-l-l-c-takes-position-in-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.